After a number of failed drug studies on Alzheimer’s disease(AD)over the past decade,clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use.However,controvers...After a number of failed drug studies on Alzheimer’s disease(AD)over the past decade,clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use.However,controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets.The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD,i.e.,amyloid-β(Aβ)and tau protein,and to explore other targets such as anti-inflammation in AD.The complex pathophysiology of AD may require combination therapies rather than monotherapy.Throughout the course of AD,multiple pathways are disrupted,presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.展开更多
基金supported by the National Key Plan for Scientific Research and Development of China(2020YFA0509304)the Chinese Academy of Sciences(XDB39000000)+4 种基金the National Natural Sciences Foundation of China(82030034 and 32121002)CAMS Innovation Fund for Medical Sciences(IFMS)(2021-I2M-C&T-B012)the Fundamental Research Funds for the Central Universities(YD9110002027 and YD9110002033)Anhui Provincial Key R&D Programs(202304295107020056)the Guangzhou Key Research Program on Brain Science(202007030008)。
文摘After a number of failed drug studies on Alzheimer’s disease(AD)over the past decade,clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use.However,controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets.The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD,i.e.,amyloid-β(Aβ)and tau protein,and to explore other targets such as anti-inflammation in AD.The complex pathophysiology of AD may require combination therapies rather than monotherapy.Throughout the course of AD,multiple pathways are disrupted,presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.
